SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-024947
Filing Date
2021-05-06
Accepted
2021-05-06 16:06:36
Documents
63
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ntla-10q_20210331.htm   iXBRL 10-Q 2204048
2 EX-10.1 ntla-ex101_147.htm EX-10.1 363706
3 EX-10.2 ntla-ex102_148.htm EX-10.2 489863
4 EX-10.3 ntla-ex103_149.htm EX-10.3 32763
5 EX-31.1 ntla-ex311_6.htm EX-31.1 21081
6 EX-31.2 ntla-ex312_8.htm EX-31.2 21097
7 EX-32.1 ntla-ex321_7.htm EX-32.1 6267
  Complete submission text file 0001564590-21-024947.txt   8947212

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA ntla-20210331.xsd EX-101.SCH 40526
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ntla-20210331_cal.xml EX-101.CAL 32202
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ntla-20210331_def.xml EX-101.DEF 137641
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20210331_lab.xml EX-101.LAB 340704
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20210331_pre.xml EX-101.PRE 256552
13 EXTRACTED XBRL INSTANCE DOCUMENT ntla-10q_20210331_htm.xml XML 1756891
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37766 | Film No.: 21897721
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Office of Life Sciences